 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Gilead Gains European Approval to Market Combination Antiretroviral Drug TruvadaFebruary 25, 2005 Foster City, Calif.-based biotech company Gilead on Wednesday received approval from the European Commission to market its combination antiretroviral drug Truvada in all 25 European Union countries, the AP/Forbes reports. Truvada is a once-daily combination pill containing the antiretroviral drugs Emtriva and Viread, known generically as emtricitabine and tenofovir, respectively. The drugs work by blocking HIV's reverse transcriptase enzyme to prevent viral replication (AP/Forbes, 2/23). The drug was approved for marketing in the United States in August 2004, according to San Francisco Business Times (San Francisco Business Times, 2/23). Back to other news for February 25, 2005
 This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Site Policies | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
